These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

855 related articles for article (PubMed ID: 17574038)

  • 21. Expression of neuronal protein synuclein gamma gene as a novel marker for breast cancer prognosis.
    Wu K; Quan Z; Weng Z; Li F; Zhang Y; Yao X; Chen Y; Budman D; Goldberg ID; Shi YE
    Breast Cancer Res Treat; 2007 Mar; 101(3):259-67. PubMed ID: 16821081
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of Her-2 Neu overexpression on outcome of elderly women treated with wide local excision and breast irradiation for early stage breast cancer: an exploratory analysis.
    Poltinnikov IM; Rudoler SB; Tymofyeyev Y; Kennedy J; Anne PR; Curran WJ
    Am J Clin Oncol; 2006 Feb; 29(1):71-9. PubMed ID: 16462507
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The expression of fascin, an actin-bundling motility protein, correlates with hormone receptor-negative breast cancer and a more aggressive clinical course.
    Yoder BJ; Tso E; Skacel M; Pettay J; Tarr S; Budd T; Tubbs RR; Adams JC; Hicks DG
    Clin Cancer Res; 2005 Jan; 11(1):186-92. PubMed ID: 15671545
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Increased expression of osteopontin in patients with triple-negative breast cancer.
    Wang X; Chao L; Ma G; Chen L; Tian B; Zang Y; Sun J
    Eur J Clin Invest; 2008 Jun; 38(6):438-46. PubMed ID: 18452545
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study.
    Arpino G; Green SJ; Allred DC; Lew D; Martino S; Osborne CK; Elledge RM
    Clin Cancer Res; 2004 Sep; 10(17):5670-6. PubMed ID: 15355892
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro clonogenic growth and metastatic potential of human operable breast cancer.
    Nomura Y; Tashiro H; Hisamatsu K
    Cancer Res; 1989 Oct; 49(19):5288-93. PubMed ID: 2766296
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A significant correlation between nuclear CXCR4 expression and axillary lymph node metastasis in hormonal receptor negative breast cancer.
    Woo SU; Bae JW; Kim CH; Lee JB; Koo BW
    Ann Surg Oncol; 2008 Jan; 15(1):281-5. PubMed ID: 17763975
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group.
    Kyndi M; Sørensen FB; Knudsen H; Overgaard M; Nielsen HM; Overgaard J;
    J Clin Oncol; 2008 Mar; 26(9):1419-26. PubMed ID: 18285604
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tumor-cell homing to lymph nodes and bone marrow and CXCR4 expression in esophageal cancer.
    Kaifi JT; Yekebas EF; Schurr P; Obonyo D; Wachowiak R; Busch P; Heinecke A; Pantel K; Izbicki JR
    J Natl Cancer Inst; 2005 Dec; 97(24):1840-7. PubMed ID: 16368946
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Survivin expression predicts early recurrence in early-stage breast cancer.
    Yamashita S; Masuda Y; Kurizaki T; Haga Y; Murayama T; Ikei S; Kamei M; Takeno S; Kawahara K
    Anticancer Res; 2007; 27(4C):2803-8. PubMed ID: 17695451
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expression and possible prognostic role of MAGE-A4, NY-ESO-1, and HER-2 antigens in women with relapsing invasive ductal breast cancer: retrospective immunohistochemical study.
    Bandić D; Juretić A; Sarcević B; Separović V; Kujundzić-Tiljak M; Hudolin T; Spagnoli GC; Cović D; Samija M
    Croat Med J; 2006 Feb; 47(1):32-41. PubMed ID: 16489695
    [TBL] [Abstract][Full Text] [Related]  

  • 32. FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.
    Badve S; Turbin D; Thorat MA; Morimiya A; Nielsen TO; Perou CM; Dunn S; Huntsman DG; Nakshatri H
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4415-21. PubMed ID: 17671124
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chemokine receptor CXCR4 overexpression predicts recurrence for hormone receptor-positive, node-negative breast cancer patients.
    Chu QD; Holm NT; Madumere P; Johnson LW; Abreo F; Li BD
    Surgery; 2011 Feb; 149(2):193-9. PubMed ID: 20598333
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chemokine receptor CXCR4 expression in colorectal cancer patients increases the risk for recurrence and for poor survival.
    Kim J; Takeuchi H; Lam ST; Turner RR; Wang HJ; Kuo C; Foshag L; Bilchik AJ; Hoon DS
    J Clin Oncol; 2005 Apr; 23(12):2744-53. PubMed ID: 15837989
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CCR7 and CXCR4 as novel biomarkers predicting axillary lymph node metastasis in T1 breast cancer.
    Cabioglu N; Yazici MS; Arun B; Broglio KR; Hortobagyi GN; Price JE; Sahin A
    Clin Cancer Res; 2005 Aug; 11(16):5686-93. PubMed ID: 16115904
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
    Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
    Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Is breast conservation therapy a viable option for patients with triple-receptor negative breast cancer?
    Parker CC; Ampil F; Burton G; Li BD; Chu QD
    Surgery; 2010 Aug; 148(2):386-91. PubMed ID: 20580045
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis.
    Pellikainen JM; Ropponen KM; Kataja VV; Kellokoski JK; Eskelinen MJ; Kosma VM
    Clin Cancer Res; 2004 Nov; 10(22):7621-8. PubMed ID: 15569994
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
    Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
    Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Patterns of relapse and metastatic spread in HER2-overexpressing breast cancer according to estrogen receptor status.
    Park YH; Lee S; Cho EY; Choi YL; Lee JE; Nam SJ; Yang JH; Ahn JS; Im YH
    Cancer Chemother Pharmacol; 2010 Aug; 66(3):507-16. PubMed ID: 19956951
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 43.